WEST PHARMACEUTICAL SERVICES INC — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
West Pharmaceutical reported Q3 2026 net sales of $874.5M (8.7% reported, 11.9% organic growth). The company raised full-year 2026 net sales guidance to $3.41–$3.42B (from $3.345–$3.380B) and adjusted-diluted EPS guidance to $9.38–$9.48 (from $8.85–$9.05). High-Value Product (HVP) Components drove growth at 20.3% organic, representing 53% of total sales. The company completed the divestiture of SmartDose 3.5mL to AbbVie, recording a $55.7M gain. Capital expenditures were reduced to $215–$220M guidance from prior $250–$275M. Share repurchases totaled $685M year-to-date.
Why this rating
Meaningful guidance raise (3–5% higher EPS midpoint) supported by strong organic growth in high-margin HVP business; modest relative to $15.7B market cap but signals execution momentum and improved 2026 outlook.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.